跳至主要内容
临床试验/JPRN-jRCTs041210104
JPRN-jRCTs041210104招募中2 期

Multicenter clinical trial to evaluate the efficacy of rituximab combination chemotherapy for children or AYAswith localized mature B-cell lymphoma - JPLSG-B-NHL-20

Sekimizu Masahiro0 个研究点目标入组 100 人开始时间: 2021年11月22日最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 6month old 至 < 26age old(—)
性别
All

入选标准

  • (1) Histologically or cytologically proven B-cell malignancies, either Burkitt lymphoma or diffuse large B-cell NHL or aggressive mature B-cell NHL non other specified or specifiable.
  • (2) (Low risk) resected Stage I/II, (Intermediate risk) unresected Stage I/II, Stage III with elevated LDH level (LDH (3) 6 months to less than 26 years of age at the time of consent.
  • (4) Newly diagnosed and untreated except for short term steroid (=< 7days)
  • (5) Available for prescribed follow-up and control of therapeutic toxicity.
  • (6) Written informed consent obtained from the patient and/or legally acceptable representatives.
  • (7) Consent to JPLSG-CHM-14 study (3rd edition and above)

排除标准

  • (1) PMLBL, Follicular lymphoma, MALT and nodal marginal zone lymphoma
  • (2) Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ
  • transplantation, previous malignancy of any type, or known positive HIV serology.
  • (3) Evidence of pregnancy or lactation period.
  • (4) Exclusion criteria related to rituximab
  • 4-1) Tumor cell negative for CD20
  • 4-2) Prior exposure to rituximab.
  • 4-3) Severe active viral infection,
  • 4-4) Severe uncontrolled infection
  • 4-5) Hepatitis B carrier status history of HBV or positive serology.
  • 5) Judged inappropriate by the doctor

研究者

发起方
Sekimizu Masahiro

相似试验